Psoriasis news, research and new treatments - DermatologyTimes
Dermatology Times
Psoriasis

FDA approves Stelara for treatment of psoriasis

October 6, 2009

Horsham, Pa. ? The U.S. Food and Drug Administration (FDA) has approved the biologic Stelara (ustekinumab, Centocor Ortho Biotech) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, according to a Centocor press release.

’Crystel’ clear: Study shows etanercept improves depression, anxiety in psoriasis patients

September 2, 2009

International report — Etanercept therapy helps to improve symptoms of depression and anxiety long-term in patients suffering from moderate-to severe psoriasis, according to the results of the Crystel study.

Golimumab eases PsA: Benefits of once-monthly anti-TNF treatment sustained for at least two years

September 1, 2009

Results have been analyzed from 276 patients followed for two years in the phase 3 trial of golimumab for the treatment of psoriatic arthritis. The data shows sustained benefits with no new safety signals emerging.

TNF blockers boost risk of lymphoma, FDA says

August 5, 2009

Washington — The Food and Drug Administration (FDA) says an increased risk of lymphoma and other cancers is associated with the use of drugs like Remicade (Centocor) and Humira (Abbott) in children and adolescents, the Wall Street Journal reports.

Nail psoriasis: Anti-TNF agents safe, effective in managing disease

August 1, 2009

Systemic therapies, particularly anti-tumor necrosis factor (TNF) agents, are an appropriate course of therapy for patients with nail psoriasis.

Unraveling psoriasis: Basic science, clinical research provide new insights on immunologic basis

August 1, 2009

Findings from multiple types of studies point to IL-23 as a master cytokine in the pathogenesis of psoriasis.

Anti-TNF safety: Medical comorbidities present psoriasis treatment challenges

August 1, 2009

As psoriasis patients may have medical comorbidities that would have excluded them from participation in premarketing clinical trials, clinicians must turn to other sources for data to guide therapeutic decisions.

Treating psoriatic arthritis: One-year data positive for sustained, significant benefits of golimumab

June 1, 2009

The investigational anti-tumor necrosis factor (TNF) monoclonal antibody golimumab (Centocor) is being evaluated as a once-a-month subcutaneous injection for the treatment of psoriatic arthritis in a Phase 3 trial that enrolled approximately 400 patients.

Maintaining control: Effective therapy improves quality of life for psoriasis patients

June 1, 2009

Ustekinumab (Centocor) pivotal trial data provide further evidence of the quality-of-life benefits derived when patients with moderate-to-severe psoriasis can maintain disease control.

Practice ToolsPractice Tools
Coding Counselor
Coding Counselor

Simple and accurate ICD-9 code search. Start Here

Formulary Counselor
Formulary Counselor

Find health plan drug coverage in your area. Start Here

Patient Education
Patient Education

Print customized patient education handouts. Start Here

Surgical Video Center
Surgical Video Center

On-demand surgery demos and presentations. Start Here



Click here